IDH1 AND IDH2 GENE MUTATIONS

The IDH1 and IDH2 gene mutation test is a molecular diagnostic assay used to detect mutations in the isocitrate dehydrogenase 1 and 2 genes, which are commonly associated with certain types of cancers, including gliomas, acute myeloid leukemia (AML), and cholangiocarcinoma. These mutations result in abnormal enzyme function that contributes to the growth and survival of cancer cells. Identifying these mutations not only assists in accurate diagnosis and classification of the cancer but also has therapeutic implications, as targeted inhibitors are available for mutated IDH1/2.

 The test is typically conducted on tumor tissue obtained through biopsy or resection. DNA is extracted from the sample and analyzed using PCR-based sequencing methods or next-generation sequencing (NGS) to detect mutations at specific hotspots in the IDH1 and IDH2 genes. Some blood-based or liquid biopsy approaches may also be used, especially in leukemia cases.

A positive result indicates the presence of a pathogenic mutation in either the IDH1 or IDH2 gene. This information can help guide prognosis and treatment planning, particularly in gliomas, where IDH-mutant tumors tend to have a better prognosis than wild-type counterparts. It also opens the door to treatment with IDH inhibitors in applicable cancer types.

 Patients diagnosed with brain tumors, AML, or other cancers where IDH mutations are known to play a role may be recommended this test. It helps in both initial diagnosis and determining eligibility for targeted therapies.

 No specific preparation is required from the patient. The test is typically done on stored tissue or biopsy samples already collected during clinical evaluation.